Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients With Recurrent or Metastatic Biliary Tract Cancer

Cancer Research and Treatment - South Korea
doi 10.4143/crt.2017.526
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Korean Cancer Association

Related search

A Multicenter Phase II Study of S-1 for Gemcitabine-Refractory Biliary Tract Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2013English

Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial

Breast Care
SurgeryOncology
2011English

Randomized Phase II Trial of First-Line Treatment With Tailored Irinotecan and S-1 Therapy Versus S-1 Monotherapy for Advanced or Recurrent Gastric Carcinoma (JFMC31-0301)

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2011English

P-161 * a Phase I-Trial Assessing Several Schedules of Oral S-1 Combined With Fixed Doses of Oxaliplatin and Irinotecan in Patients With Advanced or Metastatic Digestive Adenocarcinoma as First- Or Second-Line Treatment

Annals of Oncology
MedicineOncologyHematology
2015English

Capecitabine and Irinotecan as First- Line Chemotherapy for Patients With Metastatic Colorectal Cancer

Journal of IMAB - Annual Proceeding (Scientific Papers)
Dentistry
2011English

"Poker" Association of Weekly Alternating 5-Fluorouracil, Irinotecan, Bevacizumab and Oxaliplatin (FIr-B/FOx) in First Line Treatment of Metastatic Colorectal Cancer: A Phase II Study

BMC Cancer
Cancer ResearchOncologyGenetics
2010English

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-Line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Phase II Study on the Combination of Irinotecan Plus Cisplatin as a Second-Line Therapy in Patients With Advanced or Recurrent Gastric Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy